- Home
- KINS vs DSGN Comparison
KINS vs DSGN Comparison
Compare KINS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- DSGN
- Stock Information
- Founded
- KINS 1886
- DSGN 2017
- Country
- KINS United States
- DSGN United States
- Employees
- KINS N/A
- DSGN N/A
- Industry
- KINS Property-Casualty Insurers
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- KINS Finance
- DSGN Health Care
- Exchange
- KINS Nasdaq
- DSGN Nasdaq
- Market Cap
- KINS 189.6M
- DSGN 208.9M
- IPO Year
- KINS N/A
- DSGN 2021
- Fundamental
- Price
- KINS $15.00
- DSGN $6.55
- Analyst Decision
- KINS
- DSGN
- Analyst Count
- KINS 0
- DSGN 0
- Target Price
- KINS N/A
- DSGN N/A
- AVG Volume (30 Days)
- KINS 118.2K
- DSGN 190.0K
- Earning Date
- KINS 11-06-2025
- DSGN 11-05-2025
- Dividend Yield
- KINS 1.34%
- DSGN N/A
- EPS Growth
- KINS 325.10
- DSGN N/A
- EPS
- KINS 2.04
- DSGN N/A
- Revenue
- KINS $183,702,376.00
- DSGN N/A
- Revenue This Year
- KINS $37.94
- DSGN N/A
- Revenue Next Year
- KINS $8.63
- DSGN N/A
- P/E Ratio
- KINS $7.34
- DSGN N/A
- Revenue Growth
- KINS 28.36
- DSGN N/A
- 52 Week Low
- KINS $10.45
- DSGN $2.60
- 52 Week High
- KINS $22.40
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- KINS 55.08
- DSGN 53.15
- Support Level
- KINS $14.37
- DSGN $6.16
- Resistance Level
- KINS $15.09
- DSGN $6.77
- Average True Range (ATR)
- KINS 0.47
- DSGN 0.45
- MACD
- KINS -0.01
- DSGN 0.02
- Stochastic Oscillator
- KINS 53.90
- DSGN 71.38
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.